Table 3.
Overall activity and predictors of response
| Response | Time on venetoclax, days | Cytogeneticsa | IDH mutation | FLT3-ITD | BCL-2 family protein index at screening | |
|---|---|---|---|---|---|---|
| Response that met IWG criteria | CR | 247 | Normal | – | – | – |
| CRi | 256 | Normal | Y | – | Sensitive | |
| CRi | 170 | Complex; del(7q) | – | – | Resistant | |
| CRi | 119 | Normal | Y | – | – | |
| CR | 107 | Normal | Y | – | – | |
| CRi | 83 | Normal | Y | – | – | |
|
| ||||||
| Median (range) = | 144.5 (83–256) | |||||
|
| ||||||
| Anti-leukemic activity that did not meet IWG criteria | SDb | 247 | Normal | – | – | – |
| SDc | 143 | Complex; del(7q) | – | – | – | |
| SDd | 106 | del(7q) | Y | – | Sensitive | |
| SDe | 104 | Normal | Y | – | Sensitive | |
| SD | 128 | Complex; t(8;12) | – | – | Resistant | |
| SDf | 86 | Normal | – | Y | Sensitive | |
|
| ||||||
| Median (range) = | 117 (86–247) | |||||
a
Most common cytogenetic abnormalities were evaluated for all patients at the investigator sites.
b
≥50% bone marrow blast reduction at week 5 and recovery of hemoglobin and platelets.
c
≥50% bone marrow blast reduction at week 12 and recovery of neutrophils and hemoglobin.
d
Both with ≥50% bone marrow blast reduction and recovery of a single cell line (hemoglobin).
e
≥50% bone marrow blast reduction with no hematologic recovery.
f
FLT3-ITD mutation not confirmed at study entry, assay sensitivity was less than 0.1%..